At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SHPH Shuttle Pharmaceuticals Inc
Closed Good Friday 04-17 16:00:00 EDT
0.2535
-0.0025
-0.98%
盘后0.2600
+0.0065+2.56%
19:56 EDT
| High0.2582 | Low0.2300 | Vol414.30K |
| Open0.2500 | D1 Closing0.2560 | Amplitude11.02% |
| Mkt Cap1.59M | Tradable Cap1.41M | Total Shares6.26M |
| T/O100.80K | T/O Rate7.46% | Tradable Shares5.55M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Shuttle Pharmaceuticals Files Provisional US Patent to Treat Prostrate Cancer
MT Newswires Live · 04-10
BRIEF-Shuttle Pharmaceuticals Files Provisional Patent Application For PSMA Ligand Conjugates To Treat Prostate Cancer
Reuters · 04-10
Shuttle Pharmaceuticals- Files Provisional Patent Application for Psma Ligand Conjugates to Treat Prostate Cancer
THOMSON REUTERS · 04-10
Shuttle Pharmaceuticals files provisional patent application with USPTO
TIPRANKS · 04-10
Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer
GlobeNewswire · 04-10
Shuttle Pharmaceuticals Holdings Inc - on March 21, Enters Consulting Agreement With Bowery Consulting - SEC Filing
THOMSON REUTERS · 03-25
Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering
THOMSON REUTERS · 03-13
BRIEF-Shuttle Pharmaceuticals Holdings Offers Up To 10,000,000 Shares Of Common Stock
Reuters · 03-05
Shuttle Pharmaceuticals Holdings Inc - Offering up to 10,000,000 Shares of Common Stock
THOMSON REUTERS · 03-05
BRIEF-Shuttle Pharmaceuticals Holdings Enters $2 Million Revolving Loan Agreement
Reuters · 02-28
Shuttle Pharmaceuticals Holdings Inc - Enters $2 Million Revolving Loan Agreement
THOMSON REUTERS · 02-28
Shuttle Pharmaceuticals FY24 EPS $(3.30) Vs $(3.53) YoY
Benzinga · 02-26
Shuttle Pharma Provides Corporate Update and Reports 2024 Results
GlobeNewswire · 02-26
Shuttle reaches milestone in enrollment for Phase 2 trial of Ropidoxuridine
TIPRANKS · 01-21
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients With Glioblastoma
THOMSON REUTERS · 01-21
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
GlobeNewswire · 01-21
Shuttle Pharmaceuticals enters into sponsored research agreement with UCSF
TIPRANKS · 2024-12-19
Shuttle Pharma Enters Into Sponsored Research Agreement With the University of California, San Francisco to Advance Psma Development Program
THOMSON REUTERS · 2024-12-19
Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program
GlobeNewswire · 2024-12-19
Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program
Shuttle first patient enrollment, dosing in Phase 2 Ropidoxuridine line
TIPRANKS · 2024-11-26
Introduction
Company Name.
Shuttle Pharmaceuticals Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas, SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers. The company was founded in 2012 and is based in Rockville, Maryland.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App